Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more

NDAQ:PULM - Post Discussion

Pulmatrix Inc > Wainwright Report $5 Target
View:
Post by dmacd on Mar 12, 2019 7:34pm

Wainwright Report $5 Target

Discounted success by 10 factor so max upside is $50/sh based on assumptions. Indicates $15M/a spend till 2023 but didn't factor in dilution so I was unclear on these assumptions. Also $60M to FDA approval seems high as does the 2023 timing seem long.
Comment by dmacd on Apr 01, 2019 11:31am
A nice day for sure and validates what a few of us have known for some time now that the company was ridiculously undervalued. The deal today is worth about $40M based on upfront costs and development costs but more importantly it limits the dilution for investors since it would have taken about $40M to finish Ph 2 and 3 and the partner will pony up 50%. Once Ph 2 is complete then Pulmatrix ...more  
Comment by dmacd on Apr 04, 2019 9:51am
However the incompetent finance team issues yet another awful financing. Only an idiot would issue more warrants st this stage. Total incompetence.
Pulmatrix Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities